Cargando…

Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses

Detalles Bibliográficos
Autores principales:	Bray, Mike, Rayner, Craig, Noël, François, Jans, David, Wagstaff, Kylie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172803/ https://www.ncbi.nlm.nih.gov/pubmed/32330482 http://dx.doi.org/10.1016/j.antiviral.2020.104805

Ejemplares similares

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
por: Caly, Leon, et al.
Publicado: (2020)

Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
por: Jans, David A., et al.
Publicado: (2020)

The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
por: Jans, David A., et al.
Publicado: (2021)

Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters
por: Bramstedt, Katrina A.
Publicado: (2020)

FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010–2020
por: Rathore, Anurag S., et al.
Publicado: (2022)

Author Response to Letter to the Editor
por: Ha, Jongmok, et al.
Publicado: (2019)

Author Response to Letter to the Editor
por: Castrillo-Fraile, Victoria, et al.
Publicado: (2020)

Letters to the Editor / Author’s reply
por: Ozdemir, Mikail, et al.
Publicado: (2022)

Letter to the Editor: Authors' Response
por: Cetin, Mehtap Bilgin, et al.
Publicado: (2022)

Authors reply to letter to the editor
por: Al-Essa, Rakan S., et al.
Publicado: (2023)

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus
por: Wagstaff, Kylie M., et al.
Publicado: (2012)

Conservation of Importin α Function in Apicomplexans: Ivermectin and GW5074 Target Plasmodium falciparum Importin α and Inhibit Parasite Growth in Culture
por: Walunj, Sujata B., et al.
Publicado: (2022)

Ocular monkeypox as an emergency warning for ophthalmologists: a letter to editor
por: Karbalaei, Mohsen, et al.
Publicado: (2023)

An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims
por: Chatterjee, Satabdi, et al.
Publicado: (2012)

Response from Authors to the Letter to the Editor
por: Appendino, Juan Pablo, et al.
Publicado: (2021)

Authors’ reply to Hansel’s letter to the editor
por: Kotani, Yuki, et al.
Publicado: (2023)

Warnings of risks associated with ivermectin use for COVID-19
Publicado: (2021)

Widespread Interest in Eugenics
Publicado: (1912)

Letter to the Editor: Publication Activity of Scientific Authors
por: Joob, Beuy, et al.
Publicado: (2016)

Authors' Response to Letter to the Editor. Fake Union
por: Oba, Hiroki, et al.
Publicado: (2023)

Institutional response to FDA warning on aprotinin and impact on outcomes
por: Swaminathan, M, et al.
Publicado: (2009)

Letter to the Editor: How to raise the interest for neurogastroenterology among young gastroenterologists?
por: Upadhyaya, Advait, et al.
Publicado: (2022)

Editor-in-Chief’s Letter to Readers and Authors of Marine Drugs
por: Taglialatela-Scafati, Orazio
Publicado: (2021)

Response from the authors to the letter to editor (MVR in infants)
por: Dave, Hitendu
Publicado: (2021)

Author’s reply to the Letter to the Editor from Mungunpuntipantip and Wiwanitkit
por: Girolami, Ilaria
Publicado: (2023)

TGA warns against buying ivermectin online from unverified sources
Publicado: (2022)

Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors
por: Gasparyan, Armen Yuri, et al.
Publicado: (2013)

The Effects of the FDA Warning on the Use of Droperidol by U.S. Emergency Physicians
por: Richards, John R., et al.
Publicado: (2003)

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing
por: Yim, Seon-Hee, et al.
Publicado: (2014)

Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin
por: Croci, Romina, et al.
Publicado: (2016)

Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model
por: Mohite, Namosha, et al.
Publicado: (2021)

Author reply to Letters to the Editor “COVID-19 pneumonia in Taiwan”
por: Cheng, Shao-Chung, et al.
Publicado: (2020)

Authors’ response to Ashley Roberts’ letter to the editor on aspartame and cancer
por: Landrigan, Philip J., et al.
Publicado: (2021)

Response from Authors to Letter to Editor ‘In Search of Unity in Diversity’
por: Selvan, Chitra, et al.
Publicado: (2022)

An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
por: Chaloupka, Frank J, et al.
Publicado: (2015)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Public Perceptions of Breast Implant Complications and the FDA Boxed Warning on Implants
por: Hyland, Colby J., et al.
Publicado: (2022)

Letter to the Editor: Do Brazilian Authors Not Mention Brazilian Authors or Do They Not Value the Works of Brazilian Authors?
por: Carvalho, Lúcio Honório de
Publicado: (2021)

Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?
por: Shukla, Dr. Ajay Kumar, et al.
Publicado: (2021)

Letter to the Editor [Letter]
por: Félix, Sylvie
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qunu2pakk11lfl5c2jiel5gpkm